Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019) - Horwitz, S.M.